New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg (anhydrous);  ;  ; citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg (anhydrous) - film coated tablet - 20 mg - active: citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg (anhydrous)     excipient: colloidal silicon dioxide hypromellose macrogol 6000 magnesium stearate mannitol microcrystalline cellulose titanium dioxide active: citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg (anhydrous) excipient: colloidal silicon dioxide magnesium stearate mannitol microcrystalline cellulose opadry white 03f28539 - treatment of depressive illness in the initial phase and as maintenance against potential relapse or recurrence.

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg;  ;   - film coated tablet - 20 mg - active: citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg     excipient: croscarmellose sodium hypromellose lactose monohydrate macrogol 400 magnesium stearate maize starch microcrystalline cellulose purified talc purified water titanium dioxide - treatment of depressive illness in the initial phase and as maintenance against potential relapse or recurrence.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg - film coated tablet - 20 mg - active: citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg excipient: colloidal silicon dioxide hypromellose macrogol 6000 magnesium stearate mannitol microcrystalline cellulose purified water titanium dioxide - treatment of depressive illness in the initial phase and as maintenance against potential relapse/recurrence.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg - film coated tablet - 20 mg - active: citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg excipient: croscarmellose sodium hypromellose lactose monohydrate macrogol 400 magnesium stearate maize starch microcrystalline cellulose purified talc purified water titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg - film coated tablet - 20 mg - active: citalopram hydrobromide 24.99mg equivalent to citalopram 20 mg excipient: croscarmellose sodium hypromellose maize starch (for paste) lactose monohydrate macrogol 400 magnesium stearate maize starch microcrystalline cellulose purified talc purified water titanium dioxide - treatment of depressive illness in the initial phase and as maintenance against potential relapse/recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 24.99 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: povidone; magnesium stearate; crospovidone; lactose monohydrate; microcrystalline cellulose; maize starch; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 24.99 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; magnesium stearate; povidone; lactose monohydrate; crospovidone; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - citalopram hydrobromide, quantity: 24.99 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified water; macrogol 400; microcrystalline cellulose; purified talc; croscarmellose sodium; lactose monohydrate; hypromellose; titanium dioxide; magnesium stearate; maize starch; pregelatinised maize starch - treatment of major depression

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg - citalopram, is indicated for the treatment of depression. the efficacy of citalopram hydrobromide, in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. the efficac

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg - citalopram, is indicated for the treatment of depression. the efficacy of citalopram hydrobromide, in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. the efficac